HRT After Breast Cancer: What's Actually Possible (And the Conversation You Deserve to Have)
If you've been told — flatly, without discussion — that HRT after breast cancer is not an option for you, this post is for you.
Not because I'm going to tell you that you should take HRT. I'm not a doctor, and that is not my job. But because I know what it feels like to be handed a "no" with no explanation, no conversation, and no roadmap. And because I've spent years sitting with some of the world's leading experts in this space, and what they're saying is this: the blanket "no" is not good enough. Not anymore.
First: What Nobody Told You About "Estrogen-Positive"
This was my biggest learning. The one that stopped me in my tracks.
My breast cancer was estrogen receptor positive. For years, I understood that to mean that estrogen caused my cancer. That made sense to me. It was never corrected. And it quietly shaped every conversation, or non-conversation, I had with clinicians about HRT.
But here's what's actually true.
All healthy breast cells have estrogen receptors. Estrogen receptor positive breast cancer simply means your cancer cells retained those receptors. It does not mean estrogen caused your cancer to develop. As Dr Louise Newson explained to me, if estrogen caused breast cancer, we'd see it far more commonly in younger women with the highest estrogen levels in their bodies. We don't.
And Dr Corinne Menn, an OB-GYN and menopause specialist based in the USA who has lived this from both sides, puts it plainly: the fear that estrogen caused the cancer is understandable, and it is widespread, and it is not supported by the evidence.
That distinction matters enormously. Because it changes the entire frame of the conversation about managing menopause after cancer treatment.
What the Evidence Actually Shows
I want to be honest with you: we do not have perfect data. Anyone who tells you this is black and white in either direction is not being straight with you.
What we do have is this.
A literature review published in the journal Cancer in 2022, by Dr Avrum Bluming, co-author of the popular book Estrogen Matters, looked at 25 studies examining HRT use after breast cancer, published between 1980 and 2013. Of those 25 studies, 24 showed either reduced recurrence, reduced mortality, or no difference at all. One showed a small increased risk of local recurrence, but no increased risk of metastasis or death.
Twenty published meta-analyses have reviewed this body of evidence. Not one of them shows a meaningful difference in outcomes for women who used HRT after breast cancer.
And in January 2026, a consensus review published in The Journal of the Menopause Society — authored by a multidisciplinary team including oncologists, breast surgeons, and menopause specialists, among them Dr Louise Newson — set out to formally examine the current evidence and define the role of menopausal hormone therapy after breast cancer. The review acknowledged directly what so many women already know from lived experience: that breast cancer survivors face significant menopausal symptoms as a result of their treatment, and that their options for managing those symptoms have been severely limited. Its purpose was not to dismiss the complexity, but to engage with it honestly, name the evidence gaps, and develop a framework for doing better.
This is not fringe information. This is the peer-reviewed literature, and the expert consensus is moving. Most women navigating menopause after breast cancer treatment have never been told any of it.
If you're reading this and feeling like you've missed years of information you should have had — you're not alone, and you're not behind. Download the free guide and start with the questions that matter most.
The Options That Exist — That Many Women Are Never Told About
Let's start with where many women find themselves: still in active treatment, or on adjuvant endocrine therapy, where systemic HRT is not on the table right now. This does not mean there is nothing available to you. It means the conversation needs to go further than it usually does.
Non-hormonal options for managing symptoms like hot flushes, night sweats, and sleep disruption are underutilised and often not offered until women are desperate. SSRIs, SNRIs, gabapentin, and oxybutynin are all evidence-informed options that many women have never been told about. More recently, fezolinetant — available in Australia under the brand name Veozah, and now TGA approved — offers something more targeted. It is an NK-3 receptor antagonist, developed specifically to treat hot flushes, and it works through a completely different pathway to hormones. If you have not been offered it or told it exists, it is worth raising with your GP. The Australasian Menopause Society's 2024 information sheet on non-hormonal options is a useful resource to download and take to your next appointment.
Vaginal hormones deserve a separate conversation entirely, because they are not the same as systemic HRT and the evidence around them is clear. Local vaginal oestrogen stays where it is applied, it does not circulate through the body in any meaningful way. The safety data is strong, and there is no good clinical reason for vaginal hormones to be withheld at any stage of treatment, including for women on aromatase inhibitors. And yet they are routinely withheld. If you are experiencing genitourinary symptoms and have not been offered this option, ask specifically about it.
For women who have completed treatment, the picture opens up further. The HRT formulations available today, particularly transdermal oestradiol paired with body-identical progesterone, carry a meaningfully different risk profile to the older oral formulations used in the Women's Health Initiative study. The research landscape has moved. The formulations have changed. The conversations, in too many clinics, have not.
What Shared Decision Making Actually Looks Like
Here is what I believe every woman navigating HRT options after cancer deserves. Not just access to a prescription, access to a conversation.
A conversation where her full history is on the table. Where the published evidence is shared with her, honestly, including what we know and what we don't. Where her quality of life, her sleep, her joints, her relationships, her ability to work, her sexual health, her long-term bone density and cardiovascular health and cognitive function, is treated as just as important as recurrence statistics.
A conversation where she is the one who makes the decision.
This is not a radical idea. The Australian Commission on Safety and Quality in Health Care is clear that patients have a right to be involved in decisions about their health care, and that shared decision making can improve satisfaction with care and lead to better outcomes. They advise that to make shared decision making work, you should decide what is important to you, and make your goals, values, and preferences known to your care team and your loved ones. That is your right. Not a privilege. Not something you have to earn by being a difficult patient.
The 2026 consensus review in The Journal of the Menopause Society — co-authored by Dr Louise Newson alongside oncologists, breast surgeons, and menopause specialists — is part of exactly this shift. It does not claim to have all the answers. What it does is name the uncertainty clearly, call for better research, and establish that women deserve to have this conversation with their clinicians. The core of it is not "everyone should take HRT." The core of it is: we must share what we know and what we don't, and we must let women decide.
That is what shared decision making means. It is not a luxury. It is the standard of care every woman deserves.
What This Means If You Are in This Right Now
If you are managing menopause after breast cancer treatment and you have been given a flat "no" without explanation, you are allowed to ask why. You are allowed to ask what the evidence says. You are allowed to request a referral to a menopause specialist. You are allowed to bring information to your appointment and expect it to be engaged with.
I know how exhausting that is. I know how much energy it takes to advocate for yourself when you are already depleted. I spent nearly six years doing it before I found a GP willing to sit down and work through shared decision making with me. Six years. That is not acceptable. And it doesn't have to be your story.
The Conversation Starts Here
If you want to walk into your next appointment feeling less alone and more prepared, knowing what questions to ask and how to ask them, I've put together a free guide specifically for women navigating life after cancer treatment.
It won't make the decisions for you. Nothing should. But it will give you a framework for the conversations that matter most, so you can show up to your next appointment ready to be heard.
Because surviving cancer is not the finish line. Living well is.
Sonya Lovell is the founder of MACS — Menopause After Cancer Support — and the host of the Dear Menopause podcast. She was diagnosed with breast cancer at 47 and experienced treatment-induced menopause. She is not a medical professional. Nothing in this post constitutes medical advice. Always work with your treating team when making decisions about your care
References
Australasian Menopause Society. Non-Hormonal Treatments for Menopausal Symptoms | Information Sheet. 2024. Download the information sheet
Bluming A. Hormone replacement therapy after breast cancer: it is time. Cancer. 2022. Read the paper
Glynne S, Simon J, Branson A, Payne S, Newson L, Manyonda I, Cleator S, Douek M, Usiskin S, Tobias JS, Vaidya JS. Menopausal hormone therapy for breast cancer patients: what is the current evidence? The Journal of the Menopause Society. January 2026. Read the paper
Australian Commission on Safety and Quality in Health Care. Being involved in decisions about your care. Read more
